IL2 and neoplasm: To treat immunotherapy-resistant breast cancer, IL-2-tethered exosomes derived from personalized autologous DCs pulsed with patient tumor lysates sensitized tumor cells to ICBs through lymphocyte targeting and IL-2-mediated immune cell activation55.